Biotech is shifting beyond GLP‐1s toward neurostimulation, surgery‐mimetics, live biotherapeutics and neuro‐metabolic (MC3R/MC4R) programs globally. Notable developments: Heuro Health is building a non‐invasive neuromodulation device plus digital behavioral platform and is engaging employers and payers via North Carolina’s State Health Plan RFI; AltrixBio raised $5 million Series A in September 2025 to begin first‐in‐human testing of oral intestinal coating LuCITM; Bloom Science’s live biotherapeutic BL‐001 produced −2.3% body weight vs placebo at 28 days with effect sustained two weeks and plans Phase II in 2026. These approaches aim to address GLP‐1 gaps—cost, injections, long‐term maintenance and GI toxicity—affecting customer adherence, payer coverage and market dynamics. Immediate milestones to watch are first‐in‐human/Phase II readouts and related payer and regulatory decisions.